Click Here for 5% Off Your First Aladdin Purchase!

Blinatumomab (anti-CD3&CD19) - Primary antibody, specific to CD3E; CD19, Human IgG1, Antibody of CD19;Antibody of CD3e

  • Azide Free
  • Carrier Free
  • Low Endotoxin
  • Moligand™
  • Recombinant
  • Validated
  • ≥95%(SDS-PAGE&SEC)
  • Lot by Lot
Features and benefits
  • Short Overview:

    Purity≥95% (SDS-PAGE&SEC); Endotoxin Level≤1.0EU/mg; CHO; ELISA, FACS; Unconjugated

  • Species reactivity(Reacts with): Human
    Application:
  • ELISA
  • Flow Cytometry
Item Number
Ab175475
Grouped product items
SKUSizeAvailabilityPrice Qty
Ab175475-100μg
100μg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$239.90
Ab175475-1mg
1mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,259.90

Purity≥95% (SDS-PAGE&SEC); Endotoxin Level≤1.0EU/mg; CHO; ELISA, FACS; Unconjugated

Basic Description

Product NameBlinatumomab (anti-CD3&CD19) - Primary antibody, specific to CD3E; CD19, Human IgG1
SynonymsBlincyto,bscCD19xCD3;MEDI-538;MT-103;MT103
Specifications & PurityCarrier Free, Recombinant, Low Endotoxin, Azide Free, Validated, ≥95%(SDS-PAGE&SEC), Lot by Lot
SpecificityCD3E; CD19
ConjugationUnconjugated
GradeAzide Free, Carrier Free, Low Endotoxin, Moligand™, Recombinant, Validated
Action TypeCROSS-LINKING AGENT
Mechanism of actionAntibody of CD19;Antibody of CD3e
Product Description

Blinatumomab (anti-CD3&CD19) is a bispecific monoclonal antibody which can specifically targets the CD19 antigen present on B cells. Blinatumomab (anti-CD3&CD19) can be used for the research of acute lymphoblastic leukemia.
Purity
≥95% (SDS-PAGE&SEC)
Endotoxin Level
≤1.0EU/mg

Product Properties

Light Chain Typekappa
SDS-PAGE54.05 kDa
Purification MethodNickel affinity chromatography+Molecular sieve
FormLiquid
ConcentrationLot by Lot
Storage TempStore at -80°C,Avoid repeated freezing and thawing
Shipped InIce chest + Ice pads
Stability And StorageStore at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS853426-35-4

Associated Targets

CD19 Tclin B-lymphocyte antigen CD19 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CD3E Tclin T-cell surface glycoprotein CD3 epsilon chain 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Related Documents

References

1. Mølhøj M, Crommer S, Brischwein K, Rau D, Sriskandarajah M, Hoffmann P, Kufer P, Hofmeister R, Baeuerle PA.  (2007)  CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis..  Mol Immunol,  44  (8): (1935-43).  [PMID:17083975]
2. Brischwein K, Parr L, Pflanz S, Volkland J, Lumsden J, Klinger M, Locher M, Hammond SA, Kiener P, Kufer P et al..  (2007)  Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class..  J Immunother,  30  (8): (798-807).  [PMID:18049331]
3. Aldoss I, Bargou RC, Nagorsen D, Friberg GR, Baeuerle PA, Forman SJ.  (2017)  Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors..  Leukemia,  31  (4): (777-787).  [PMID:28028314]
4. Gökbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, Diedrich H, Topp MS, Brüggemann M, Horst HA et al..  (2018)  Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia..  Blood,  131  (14): (1522-1531).  [PMID:29358182]
5. Slaney CY, Wang P, Darcy PK, Kershaw MH.  (2018)  CARs versus BiTEs: A Comparison between T Cell-Redirection Strategies for Cancer Treatment..  Cancer Discov,  (8): (924-934).  [PMID:30012854]

Solution Calculators